

EPICS

Conference Coverage: ESMO 2024 – Focus on Gastrointestinal (GI) Malignancies

19 September 2024, 8.00 AM – 11.00 AM MST/17.00 – 20.00 CEST
Virtual

Chair: Tanios S. Bekaii-Saab, MD – Mayo Clinic, Phoenix, AZ, US

Faculty

Dirk Arnold, MD, PhD – Asklepios Tumorzentrum Hamburg, Germany
 Cathy Eng, MD, FACP, FASCO – Vanderbilt-Ingram Cancer Center, Nashville, TN, US
 Philip A. Philip, MD, PhD, FRCP, FABC – Henry Ford Cancer Institute, Detroit, MI, US
 Julien Taieb, MD, PhD – Hôpital Européen Georges-Pompidou, Paris, France
 Nataliya Uboha, MD, PhD – University of Wisconsin Carbone Cancer Center, Madison, WI, US
 Alan Venook, MD, FASCO – Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, US (TBC)

DRAFT AGENDA

Time (MST/CEST)	Topic	Speaker/ Moderator
8.00 AM – 8.05 AM/ 17.00 – 17.05 (5 min)	Welcome and Introductions	Tanios S. Bekaii-Saab, MD
8.05 AM – 8.15 AM/ 17.05 – 17.15 (10 min)	Metastatic Colorectal Cancer (mCRC) – Including Targeted Therapy <ul style="list-style-type: none"> LBA25 - Randomized Phase III trial of Ramucirumab in combination with TAS102 (Trifluridin/Tipiracil) vs. TAS102 monotherapy in heavily pretreated metastatic colorectal cancer: The RAMTAS/IKF643 trial of the German AIO (AIO-KRK-0316). S. Kasper-Virchow, et al 505O – Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase 1b CodeBreak 101 study. Salvatore Siena, et al 511MO – Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: the randomized phase II CITRIC trial. Cristina Santos Vivas, et al 513MO – Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase 1b/2 study. Filippo Pietrantonio, et al 515MO – Encorafenib + Cetuximab (EC) + FOLFIRI for BRAF V600E-Mutant Metastatic Colorectal 	Julien Taieb, MD, PhD

	Cancer (mCRC): Updated Results From the BREAKWATER Safety Lead-In (SLI). Josep Tabernero, et al	
8.15 AM – 8.25 AM/ 17.15 – 17.25 (10 min)	<p>Key Questions and Topics for Discussion</p> <ul style="list-style-type: none"> • What are your views on the recently presented data? • In your view, are any of these data potentially practice changing? • What learnings can be gathered from the currently presented data to help guide treatment decisions for your patients in the early setting? • With the currently available agents and recently presented data, what do you consider optimal sequencing strategies in 3L and beyond in mCRC? What are your views on the role of chemo rechallenge in the 3L? 	Tanios S. Bekaii-Saab, MD
8.25 AM – 8.35 AM/ 17.25 – 17.35 (10 min)	<p>Microsatellite Stable (MSS) and High Microsatellite Instability (MSI-H) CRC</p> <ul style="list-style-type: none"> • LBA24 - Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2. M. Chalabi, et al • 503O – Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study. Peter G. De Gooyer, et al • 504O – IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: results of the colorectal cancer cohort. Christelle De la Fouchardiere, et al • 502O – Pembrolizumab in combination with CAPOX and bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: preliminary results of FFCD 1703 POCHI trial. David Tougeron, et al 	Dirk Arnold, MD, PhD
8.35 AM – 8.50 AM/ 17.35 – 17.50 (15 min)	<p>Key Questions and Topics for Discussion</p> <ul style="list-style-type: none"> • What are your views on the recently presented data? • With the currently available data and treatment options, what factors would drive your choice of therapy for your patients with early MSI-H CRC? • What is your current approach for using and sequencing immune checkpoint inhibitors in metastatic MSI-H tumors? • What other additional avenues should be explored to optimize treatment in MSS CRC? 	Tanios S. Bekaii-Saab, MD
8.50 AM – 8.55 AM/ 17.50 – 17.55 (5 min)	Key Takeaways: mCRC – Including Targeted Therapy + MSS and MSI-H CRC	Julien Taieb, MD, PhD, and Dirk Arnold, MD, PhD
8.55 AM – 9.05 AM/ 17.55 – 18.05 (10 min)	<p>Rectal Cancer</p> <ul style="list-style-type: none"> • 508MO – Organ preservation in early rectal adenocarcinoma: 5-year results of the randomized opera trial. Syrine Ben Dhia, et al 	Cathy Eng, MD, FACP, FASCO

	<ul style="list-style-type: none"> • 509O – Total Neoadjuvant Treatment (TNT) with Non-Operative Management (NOM) for Proficient Mismatch Repair Locally Advanced Rectal Cancer (pMMR LARC): First Results of NO-CUT Trial. Alessio Amatu, et al • 510MO – Long-Term Survival and Organ Preservation with Pembrolizumab in Localized MSI-H/dMMR Solid Tumors. Kaysia Ludford, et al. • 565P – Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Results After Minimum 3 years Follow Up. Carl J. Brown, et al 	
9.05 AM – 9.15 AM/ 18.05 – 18.15 (10 min)	Key Questions and Topics for Discussion <ul style="list-style-type: none"> • What are your views on the recently presented data? • Are any of the new data potentially practice changing in the near future in the metastatic setting? • Which additional avenues should be explored to optimize treatment in rectal cancer? 	Tanios S. Bekaii-Saab, MD
9.15 AM – 9.20 AM/ 18.15 – 18.20 (5 min)	Key Takeaways: Rectal cancer	Cathy Eng, MD, FACP, FASCO
9.20 AM – 9.25 AM/ 18.20 – 18.25 (5 min)	<i>Break</i>	
9.25 AM – 9.35 AM/ 18.25 – 18.35 (10 min)	Gastric and Gastroesophageal Junction (GEJ) Cancers <i>Early</i> <ul style="list-style-type: none"> • LBA58 - A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): final results from an intergroup trial of AGITG, TROG, EORTC and CCTG. T. Leong, et al. <i>Metastatic</i> <ul style="list-style-type: none"> • LBA59 - Modified FOLFOX plus/minus Nivolumab and Ipilimumab vs FLOT plus Nivolumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Final Results of the IKF-AIO-Moonlight trial. S. Lorenzen, et al • LBA60 - Phase 3 study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric/gastroesophageal junction adenocarcinoma (G/GEJA). Z. Peng • 1400O – Final overall survival for the phase 3, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma. Yelena Y. Janjigian, et al 	Nataliya Uboha, MD, PhD

	<ul style="list-style-type: none"> 1401O – Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03). Yelena Y. Janjigian, et al 	
9.35 AM – 9.50 AM/ 18.35 – 18.50 (15 min)	<p>Key Questions and Topics for Discussion</p> <ul style="list-style-type: none"> What are your views on the recently presented data? Are any of the new data potentially practice changing in the near future in the early and metastatic settings? Are there key updates on the choice and sequencing of agents in HER2-positive gastric and GEJ cancer? Have you seen any promising data from new investigational agents? Which additional avenues should be explored to optimize treatment in gastric/GEJ cancers? 	Tanios S. Bekaii-Saab, MD
9.50 AM – 9.55 AM/ 18.50 – 18.55 (5 min)	<p>Key Takeaways: Gastric and GEJ Cancers</p>	Nataliya Uboha, MD, PhD
9.55 AM – 10.05 AM/ 18.55 – 19.05 (10 min)	<p>Pancreatic Cancer and Biliary Tract Cancer</p> <p><i>Pancreatic cancer</i></p> <ul style="list-style-type: none"> LBA62 - Preoperative modified FOLFIRINOX (mFOLFIRINOX) with or without chemoradiation (CRT) in borderline resectable pancreatic cancer (BRPC): results from the randomized phase II trial PANDAS/PRODIGE 44. A. Lambert, et al. LBA63 - A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy. A. Gehrels, et al 1504MO – Phase 2 Trial of Pembrolizumab and OLApaRib (POLAR) Maintenance for Select Patients (pts) with Metastatic Pancreatic Cancer (mPC) with (A) Homologous Recombination Deficiency (HRD), (B) non-core HRD (ncHRD) and (C) Exceptional Response to Platinum. Wungki Park, et al <p><i>Biliary tract cancer</i></p> <ul style="list-style-type: none"> 50P – Camrelizumab (Cam) combined with gemcitabine and cisplatin (GP) plus low-dose apatinib in first-line treatment of advanced biliary tract cancer (BTC). Yunxin Lu, et al 44P – Chemo-Immunotherapy combination of mFOLFOX6, bevacizumab and atezolizumab after first line therapy for advanced biliary tract cancer – the COMBATBIL imCORE trial. Mariano Ponz-Sarvisé, et al 	Philip A. Philip, MD, PhD, FRCP, FABC

<p>10.05 AM – 10.20 AM/ 19.05 – 19.20 (15 min)</p>	<p>Key Questions and Topics for Discussion</p> <ul style="list-style-type: none"> • What are your views on the recently presented data in pancreatic and biliary tract cancers? • Have any novel therapies of special interest in pancreatic cancer been presented? • Which chemo regimen do you choose and why, for 1L treatment of metastatic pancreatic cancer, and what factors determine your sequencing strategy? • What are your thoughts on molecular profiling and when to test in biliary tract cancer? • Do you see the treatment landscape in biliary tract cancer shifting with the integration of immunotherapy and targeted approaches? 	<p>Tanios S. Bekaii-Saab, MD</p>
<p>10.20 AM – 10.25 AM/ 19.20 – 19.25 (5 min)</p>	<p>Key Takeaways: Pancreatic Cancer and Biliary Tract Cancer</p>	<p>Philip A. Philip, MD, PhD, FRCP, FABC</p>
<p>10.25 AM – 10.40 AM/ 19.25 – 19.40 (15 min)</p>	<p>Hepatocellular Carcinoma (HCC)</p> <ul style="list-style-type: none"> • LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study. J. Llovet, et al • LBA38 – Iparomlimab and tivozalimab (QL1706) with bevacizumab and/or chemotherapy in first-line (1L) treatment of advanced hepatocellular. S. Quin, et al • LBA39 - Updated efficacy and safety data from IMbrave050: Phase 3 study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). A. Yopp, et al • LBA40 - Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). J. Zhou, et al. • 964P – Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): an international, multicenter, phase 4 study (STELLAR). Markus Peck Radosavljevic, et al • 985P – Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: the pivotal phase 3 study of camrelizumab + rivoceranib in unresectable hepatocellular carcinoma (uHCC). Ahmed O. Kaseb, et al 	<p>Alan Venook, MD, FASCO</p>
<p>10.40 AM – 10.55 AM/ 19.30 – 19.55 (20 min)</p>	<p>Key Questions and Topics for Discussion</p> <ul style="list-style-type: none"> • What are your views on the recently presented data? • Are any of the new data potentially practice changing in the near future in the metastatic setting? • Which additional avenues should be explored to optimize treatment in HCC? 	<p>Tanios S. Bekaii-Saab, MD</p>

	<ul style="list-style-type: none"> How do you see the field evolving over the next 5 years? 	
10.55 AM – 11.00 AM/ 19.55 – 20.00 (5 min)	Key Takeaways: HCC	Alan Venook, MD, FASCO
11.00 AM/ 20.00	Summary and Closing Remarks	Tanios S. Bekaii- Saab, MD

Total time: 3 hours